series-c-plus
Stage
2015
Founded
5
Investors
About
C4 Therapeutics develops targeted protein degraders, a novel class of medicines that harness targeted protein degradation to treat diseases such as multiple myeloma, with clinical candidates like cemsidomide in Phase 1 trials.
Explore C4 Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.